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HISTOPATHOLOGY OF LARGE-CELL LYMPHOMAS
A. E. STUART
From the Untiversity Department ofPathology, Royal Victoria Infirmary,
Newcastle upon Tyne NEI 4LP
PATHOLOGISTS have recognized for many
years that two important factors in the
prognosis of malignant lymphoma are the
size ofthe neoplastic cells and the presence or
absence of a follicular pattern. Tumours com-
posed of small cells or possessing a follicular
structure occupy the benign end ofa spectrum
of malignancy. Despite the looseness of
definition and the profound effects of fixation
on cell size, there is a general awareness that
the old terms "reticulum cell sarcoma" and
"histiocytic tumour" refer to large-cell
neoplasms. Today there is a tendency to have
within this category a number of subgroups
which have arisen from defined cells found in
the germinal centres of lymphoid tissue.
These are:
(1) Large centrocytes: these cells have an
irregular nuclear outline, an inconspicuous
nucleolus and abundant cytoplasm. They are
common in reactive follicle centres hut less so
in neoplasms.
(2) Centroblasts: the nuclei are about the
same size as those of macrophages and are
round and vesicular. They have up to 4
nucleoli, often close to the nuclear membrane,
and a thin rim ofpyroninophilic cytoplasm.
(3) Immunoblasts: these are found in the
germinal centres and also in the interfollicular
areas of lymphoid tissue. The nucleolus is
usually single and central and the cytoplasm
is strongly pyroninophilic. They may show
plasmacytoid differentiation (plasmablastic).
These cell types give rise to 3 recognizable
morphological subgroups of neoplasm; i.e.
(1) large centrocytic, (2) centroblastic, (3)
immunoblastic and plasmablastic. Immuno-
peroxidase methods which detect cytoplasmic
immunoglobulin enable us to distinguish
between blast cells containing Ig and those
without.
A fourth group, still controversial and
awaiting further research with marker
studies, is thought to be composed of large
neoplastic histiocytes. At present these are
rarely recognized.
In addition, tumours composed of pleo-
morphic large and multinucleated giant cells
which defy precise categorization are en-
countered. Some of these may prove to be
epithelial or mesenchymal in origin. Thus, we
have 5 subgroups of large-cell tumour which
can be recognized by the hospital pathologist
using a light microscope and routine staining
procedures. When marker studies are added,
some ofthese groups can often be shown to be
derived from B or T lymphocytes.
These large-cell tumours, with the excep-
tion of the large centrocytic type, are highly
aggressive and pose a challenge to all con-
cerned with their management. An important
contribution to this management may rest
with clear recognition of the tumour sub-
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SURFACE PHENOTYPES OF LARGE-CELL LYMPHOMA
A. J. HABESHAW
From the Department of Medical Oncology, St Bartholomew's Hospital, London EC1A 7BE
LARGE-CELL LYMPHOMAS (LCL) form a
heterogeneous group which poses a continuing
diagnostic problem. This summarydocuments
the result ofattempts to define these tumours
by surface phenotype in the hope ofidentify-
ing the groups with good and bad prognosis,
since about one third of patients with LCL
show significant long-term survival with
present modes of treatment.
Using the Kiel classification, large-cell
lymphomas fall into the groups (1) immuno-
blastic lymphoma, (2) centroblastic lymph-
oma, (3) high grade unclassified. Centrocytic
tumours of large-cell type are usually re-
garded as large-cell lymphomas. These cate-
gories are equivalent to DHL of Rappaport.
The "high grade unclassified" group is quite
distinct from the category of unclassified
"lymphoblastic lymphoma". The data re-
ported here are concerned with patients whose
histological diagnoses were of immunoblastic
lymphoma (MLIB, 11 cases), centroblastic
lymphoma (MLCB, 4 cases), malignant
lymphoma ofhighgradeunclassified(MLHgU,
6 cases), centrocytic lymphoma of large cell
type (MLCC/LC, 2 cases) and malignant
histiocytosis (MH, 1 case).
The phenotyping was always performed on
fresh viable cells obtained on surgical biopsy
of lymph node or tumour mass. In each case
the suspension was tested for E rosettes, Fcy
and Fc, rosettes, C3d rosettes, surface and
cytoplasmic immunoglobulin. Antisera speci-
fic for T cells (HTLA) and anti-Ia (HLA D)
were used in some cases. Phagocytes were
quantitated by their Neutral Red uptake.
The phenotypic profile was obtained and
evaluated independently of the histological
TABLE I.-Phenotyping of large-cell tumours
classified as high-grade lymphoma
Total
Monoclonal B cell
T cell
Monocyte/macrophage
Null
No. %
24 100
11 46
6 25
4 16
3 12
evaluation, as previously reported (Habe-
shaw et al., 1979). The patients reported here
form part of the Bart's Chemotherapy Trial
and were allotted to the high-grade chemo-
therapy/radiotherapy arm of that trial after
complete staging procedures and documenta-
tion of symptomatology and haematological
parameters.
Of the total of 24 cases of LCL, character-
ized by phenotype, 11 cases were clearly of
B-cell type, 6 were of T-cell type, 4 had the
phenotypic and functional characteristics of
FIGURE.-Survival curve for all B-cell tumours;
capping vs non-capping. P = 0-0673.
TABLE II.-Surface markers of B-cell lymphomas oflarge-cell type
C3 Ig class
- MDK
- ML
- MGL
+ MGK
- GL
- MK
- GK
- MK
- ML
- ML
- M+AL
E rosettes Histology
34 MLIB
5 MLIB
1 MLIB
40 MLIB
12 MLIB
1 MLIB
30 MLIB
9 MLCB
14 MLCB
10 MLCC/LC
8 MLCCILC
Patient
T
A
J
S
W
MS
C
G
K
M
D
SIgC
0
22
14
0
0
0
39
36
15
3
0
SIgNc
78
49
46
50
80
70
12
22
78
75
66
CyIg
+
+
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TABLE III.-Phenotype of T-cell tumours of
large-cell type
Patient T cells
Ha 90
G 53
Hu 79
Mo 66
C 64
Md 89
B cells
3
26
10
15
10
5
Mono-
nuclear
phagocytes Histology
(Oo)
0
18
15
1
:3
1
MILIB
AILIB
MILIB
MLCB
MLHgU
MLHgU
mononuclear phagocytes, and 3 cases wvere of
indeterminate phenotypic characteristics
(Null) (Table I).
The phenotype of the patients with B-cell
lymphoma are shown in Table II. High-grade
B-cell lymphomas show non-capping surface
Ig, a feature related to survival (Figure) in
which the survival characteristics of capping
B-cell lymphomas in the series (40 patients)
are compared with the survival of non-
capping B-cell tumours (11 patients) ofother-
wise equivalent phenotype. Most non-capping
B-cell tumours are histologically high-grade
lymphomas. Nine of the 11 patients wiith
high-grade B-cell tumours have died within
2 years of diagnostic biopsy.
T-cell tumours were present in 6 patients
with LCL lymphoma (Table III). Of these, 3
w%Nere histologically classified as MLIB, 1 as
MLCB, and 2 as MLHgU. The numbers of
accompanying B cells in these cases varied
from 3%0 to 30,0o with no evidence of B-cell
monoclonalitv. Four cases tested for TdT
proved negative, establishing that these
T-cell neoplasms are not derived from im-
mature precursors, but from peripheralized
mature TH or Ts subsets. All 6 patients with
high-grade T-cell lymphoma have died, the
longest survival in this group being about 300
days.
Tumours containing many functional
mononuclear phagocytes (Table IV) are
TABLE IV-.Surface marker of high-grade
lymphomas of "mononuclear phagocytic"
type
Functional
phago-
Patient cytes
(Oo)
Ca 60
OL 38
A 18
H 18
FCy
(%o)
60
55
69
54
B
cells
5
25
11
3
T
cells Histology
(%o)
19 MLIB
24 MH
32 HgU
20 HgU
poorly characterized; there is difficulty in
interpreting the histological appearances and
phenotypic features. The criteria used here
are:
(1) Substantial numbers of functional
phagocytes.
(2) Fcy receptor on > 25% of cells.
(3) Absence of monoclonal B-cell popula-
tion.
(4) Mononuclear phagocytes (SIg- Fcy+
phenotype) are numerically the largest
definable cell population.
Ofthe 4 cases meeting these criteria, 2 were
diagnosed as MLHgU, one as MLIB, and one
as MH. Null-cell tumours occurred in 3 cases
(Table V). Null-cell tumours are lymphomas
with none of the established features of B
cells, T cells or mononuclear phagocytes.
The tumour cells may exhibit Fey or C3d
receptors, but are not obviously phagocytic.
In patient M, the presenting feature was
hypogammoglobulinaemia. All patients with
null-cell tumours had nodal presentations of
TABLE V.-Surface markers of large-cell tumours classified as "null"
Patieit T cells B cells I'hagocytes
() (O/o) (Oo)
Mo I 10 0
Br 15 7 0
Hp 38 12
TABLE VI.-Relationship ofphenotype to histology of large-cell lymphoma
Phenotype:
B cell
T cell
Monoinulclear plhagocyte
Null
AILIB MILCB AILCC/LC MLHgU
7
3
1
0
Total 11
I
1
4
(1
0
2
6
Fcy
(%)
20
25
11
C3d
15
44
13
CyIg
( ,/o) (0)
0
0
Histology
MLHgU
MLHgU
MLCB
MH
0
0
1
I
Total
11
6
4
3
24
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disease, without extranodal involvement. Of
the 7 patients with mononuclear phagocyte or
null-cell tumours, only one has died; the
longest survivor remained disease-free 1318
days from biopsy.
A measure of the utility of any histological
classification is the degree to which that
classification can be used to predict the
clinical behaviour of a single category of
disease. As shown here, the phenotypic
characteristics in this group of lymphomas
show only a limited fit with the categories
established morphologically. Immunoblastic
lymphomas may be either ofB- or T-cell type,
but one of the presenting cases in this series
was phenotypically of functional phagocytes.
Similarly the categories of centroblastic
lymphoma and high-grade unclassified lymph-
omashowheterogeneity ofcell type by surface
marking.
It is encouraging that these early attempts
at definitive classification of a complex group
of tumours by surface marking are beginning
to bear fruit. Classification of high-grade
lymphomas by morphology alone is probably
inadequate, in view ofthe phenotypic hetero-
geneity of the histologically classified groups
reported here. The argument for including
even simple phenotyping procedures in the
diagnosis of LCI, is strong and would, in the
author's view, resolve some of the current
controversies in this field.
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END-STAGE AND MULTI-DIFFERENTIATION-STAGE LCL AS
DISTINCT PATHOLOGICAL ENTITIES
I. C. M. MAcLENNAN
From the Department of Immunology, University ofBirmingham Medical School,
Birmingham B15 2TJ
THE EXISTENCE of multi-differentiation-
stage tumours ofthe lympho-myeloid series is
well established. Chronic granulocytic leuk-
aemia provides a prime example. Here an
oligomalignant monoclonal condition can
give rise to a highly malignant subclone which
may be eitherofthe myeloid orearly lymphoid
series. LCLs, excluding the lymphoblastic
lymphomas, are thought to be tumours of
end-stage lymphoid cells, i.e. cells which
physiologically would have been derived as
the result of antigen stimulation of small
immunologically competent precursor lymph-
ocytes. Cytoplasmic and surface-membrane
immunoglobulin studies allow one to identify
clones of neoplastic B cells with confidence,
for B cells ofa single clone are committed to
producing immunoglobulin with one light-
chain isotype and a single idiotype. Re-
circulating precursor small B lymphocytes
can be demonstrated in the blood in many
cases of low-grade lymphoma: all cases of
diffuse lymphocytic lymphoma and about
half the cases of follicle-centre-cell tumour.
When B-cell leukaemia is seen in these
diseases it is almost always overt, in that
>90% of blood B cells express the same
light-chain isotype. Such a finding is most
uncommon in LCL of the B series, and when
it is present it is difficult to be certain that
the cells in the blood are precursors of those
in the solid tumour, they might be derived
from the tumour itself. In some situations
where recirculating precursors are present
with high-grade LCL, it seems probable that
a highly malignant large-cell clone has
appeared in a multi-differentiation-stage
lymphoma oflow malignancy. This situation,
analogous to that of blast crisis of chronic
granulocytic leukaemia, is a well recognized
complication of follicle-centre-cell tumour,
i.e. mixed centroblastic/centrocytic lymph-
omas of low malignancy may give rise to
highly malignant immunoblastic lymphoma.
Also in myelomatosis, where the disease is
usually strictly confined to the marrow or
periosteal sites, immunoblastoma which
forms secondary extramedullary deposits may
occur. Whether all "multistage" LCL are of
this type remains to be determined. In suchWORKSHOP ON LARGE-CELL LYMPHOMAS
cases eradication of the highly malignant
subelone will not necessarily eliminate the
parental low-grade lymphoma.
There is good evidence for the existence of
large-cell B lymphomas as isolated solid
tumours. Stage I and IE immunoblastic
lymphomas can be successfully treated in
some cases with excision only or local
eradicative radiotherapy. The pure end-stage
LCL still offer the best possibility of cure in
the non-Hodgkin's lymphoma. This becomes
apparent when long-term survival curves of
low- and high-grade lymphoma are compared.
The high-grade lymphoma patients are at
high risk ofdying in the first year or two, but
a plateau is then reached ofapparently cured
patients. The low-grade lymphoma curve
continues slowly but relentlessly down,
meeting and crossing that of the high-grade
lymphomas by 5-8 years.
THE USE OF LECTINS IN THE STUDY OF SURFACE MEMBRANES
OF LYMPHOMAS
G. BLACKLEDGE
From the Department of Medical Oncology, Christie Hospital and Holt Radium Institute,
Manchester M20 9BX
THE MORE RECENT histological classifica-
tions ofnon-Hodgkin's lymphomas have been
based on a comparison with cell types norm-
ally found within the lymphoid system
(Lukes & Collins, 1974; Gerard-Marchant et
al., 1974). Since the lymphocyte is the pri-
mary cell involved in the immune response,
immunologic characterization of lymphoma
cells has played a large part in the develop-
ment of these classifications. Surface-mem-
brane recognition is based on cell-surface
glycoproteins and in particular their oligo-
saccharide chains. Lectins are substances
which bind reversibly but specifically to
carbohydrates or oligosaccharides, and can
thus be used to investigate the nature of the
cell-surface glycoproteins.
Using flow cytometry and fluorescent-
conjugated lectins, we have developed
methods of studying the binding of lectins to
the surface glycoproteins of lymphoid cells.
Extraction of the glycoproteins is not
necessary, and they are studied in situ on the
membrane. Flow cytometry allows for quanti-
tation ofbinding, and using a computer inter-
faced with the flow cytometer, sophisticated
analysis of cell populations can be made.
We have shown that the mannose-binding
lectin from Lens culinaris can distinguish
between human T and B lymphocytes
(Blackledge et al., 1980a). Additionally,
wheat-germ lectin (WGL), which binds to
sialic acid and N-acetyl-glucosamine, shows
greater binding to non-T cells. These observa-
33
tions led us to study the peripheral-blood
mononuclear cells ofpatients withlymphoma.
There were characteristic patterns seen in the
different histological types. Patients with
nodular poorly differentiated lymphocytic
disease (Rappaport _= follicular, centrocytic/
centroblastic, Kiel) had a great increase in
WGL binding, with a heterogeneous picture.
In contrast, patients with LCL (histiocytic
cell type (Rappaport)) showed a well defined
homogeneous population of cells with in-
creased Lens culinaris and WGL binding.
The lectin binding of the different lympho-
mas did not correspond to any patterns
seen in normal lymphocyte sub-populations.
Lectin binding is therefore assessing addi-
tional surface-membrane glycoproteins to
those involved in conventional immune
surface markers.
The opportunity therefore arises to use
lectins to study the behaviour of different
lymphomas within the body. Lymphocyte
imaging, using radioactive indium-ill oxine
can trace the circulation of lymphocytes
through the organs of the body (Wagstaff et
al., 1981). The predisposition of some lymph-
omas to present in extra-nodal sites (Black-
ledge et al., 1980b) and to have characteristic
behaviour patterns of spread and prognosis,
may be, in part, explained by the abnormal
surface glycoproteins detected by lectin
binding.
Further studies areunderway usinga wider
range of lectins to examine these phenomena.
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NON-RANDOM CHROMOSOME INVOLVEMENT IN NON-BURKITT,
NON-HODGKIN LYMPHOMA
K. L. GAUNT
From the Department of Human Genetics, University of Newcastle upon Tyne
CHROMOSOMAL ANALYSIS of lymph-node
biopsies from patients with suspected malig-
nant lymphoma was undertaken. Six ofthese
yielded abnormal banded karyotypes. There
were 4 males and 2 females, 3 with a follicular
lymphoma and 3 with a LCL. Full karyotype
analysis of the abnormal clones was obtained
for 5 patients; these had a modal chromosome
number of 45-48. In the 6th patient the
abnormal clone tended towards tetraploidy,
and although several consistent chromosome
markers were seen, no full cell was karyo-
typed. Numerical and structural abnormali-
ties were found in all cases. In the 5 patients
with full karyotype analysis, chromosome 7
was gained in 3 cases and the Y chromosome
was lost in 2 of the 4 male patients.
Structurally, the chromosome most affected
was chromosome 9, altered in4 cases. Chromo-
somes 1, 6 and 14 were altered in 3 of the
patients and chromosomes 3, 7, 11 and 18 in
2 cases.
The position of the chromosome break-
points involved in deletions and transloca-
tions was also non-random. The centromere
region of chromosome 1 was involved in 4/7
breaks; the centromere and distal terminal
band ofchromosome 3 in 2/5 rearrangements,
the distal terminal band of chromosome 9 in
3/4 rearrangements and the distal terminal
band of chromosome 14 in all 3 cases of
structural rearrangements of that chromo-
some.
Two patients, a 45-year-old female with a
follicular lymphoma ofsmall-cell type and an
85-year-old female with a follicular lymphoma
of small and large cells, had similar marker
chromosomes; the first case had a derivative
chromosome 9, t(9;1 ;1) (9pter-->9q 34: :lpter
-l>1p32::1q11-1qter) with a del l(p32) and
del l(qll), the second patient had marker
chromosomes der 9, t(9;1) (9pter-.-9q 34::
lqll-lqter) and del 1(qll). Both had 14q+
markers.
The data have been combined with 57 cases
with biopsy specimens of non-Burkitt non-
Hodgkin's lymphoma from the literature.
This confirms a frequent numerical involve-
ment of chromosome 7, which was involved
in 20% of 63 chromosomally abnormal
lymphomas. Chromosome 3 was lost or gained
in 19.0% of cases and chromosome X in
17.4%. There was a particularly high rate of
structural rearrangement of chromosome 14
(41.2%), with most ofthese structural changes
involving the terminal long-arm band 14q 32.
Chromosome 1 was involved in 38.0% of
cases, but the abnormalities produced were
not specific, and recurrent markers are rare.
Abnormalities of chromosome 1 have been
found in many malignancies, including the
myeloid leukaemias, bladder, ovarian and
cervical tumours. Abnormalities of chromo-
some 14 are rare in the myeloid malignancies
and other tumours.
It is still not understood how or why non-
random changes occur, and there is little
experimental evidence to support or direct
any theory. Because of the heterogeneous
nature of malignancy a unitary approach to
the problem of chromosomes in malignancies
may not be warranted. It would seem that in
cases such as the Philadelphia chromosome of
chronic myeloid leukaemia and translocations
involving chromosome 14 in the lymphoid
malignancies, these particular changes in
karyotype are an essential earlystep. Possibly
the more random elements of chromosome
change are the result of evolution to suit a
particular and precise microenvironment.WORKSHOP ON LARGE-CELL LYMPHOMAS
CONTEMPORARY CHEMOTHERAPY FOR LARGE-CELL LYMPHOMAS
J. M. A. WHITEHOUSE
From the C.R.C. Medical Oncology Unit, Southampton General Hospital,
Southampton S09 4XY
IMMUNOLOGICAL TECHNIQUES have per-
mitted the recognition and study of lympho-
cyte sub-populations in normal and neo-
plastic states. Despite the potential for
rationally reclassifying the non-Hodgkin
lymphomas on the basis of these studies, the
Rappaport classification remains the one
most commonly used in reporting clinical
trials. Most of the cases identified as LCL are
reported as "histiocytic diffuse", but a small
proportion are also identifiable as "diffuse
undifferentiated" in the Rappaport classifi-
cation. These together make up 25% of all
non-Hodgkin lymphomas, and 40% of the
diffuse lymphomas (DHL 31%' DUL 9%).
Pathological staging (staging laparotomy ±
whole-body scanning) reveals that most cases
are Stage IV, that the number of Stage II
cases (>20%) often exceeds those that are
Stage III (<20%) and that rather less than
10% prove to have Stage I disease.
Five-year survival for Stage I and II
disease treated primarily with radiotherapy
approaches 45%. Most series report a signifi-
cant difference in survival between patho-
logical Stage I and II disease. Stage I and
IE may be cured with radiotherapy alone in
75% of cases, whilst 30-40% of Stage II
and IIE disease are cured by a combination
of surgery and radiotherapy. Recent reports
by Miller and Jones of a few cases with Stage
I or II diffuse histiocytic lymphoma treated
with either chemotherapy and radiotherapy,
or chemotherapy alone, show no significant
survival advantage for either approach. In
view of the high risk of relapse in Stage I1
disease and the median disease-free survivals
exceeding 23 months in 95% oftheir patients,
first-line therapy for this group merits further
clinical trials.
Stage III and IV diffuse histiocytic lymph-
omas should always receive combination
chemotherapy (the role of radiotherapy in
these patients is not established). Several
careful studies from major centres have
identified complete-response rates of 50% or
more (with C-MOPP, BACOP, CHOP, HOP,
OPAL or COMLA) median survivals exceed 3
years, and about halfofthe patients achieving
complete remission may prove to be cured.
Survival of partial remitters and non-
responders do not differ significantly. Poor
prognostic factors include Stage IV disease,
marrow involvement, CNS involvement,
gastrointestinal involvement, and a tumour
mass exceeding 10 cm diameter. Constitu-
tional "B" symptoms have also been re-
ported to be associated with a poorer prog-
nosis than those without symptoms. The
difference in outlook between Stages III and
IV disease is now emphasized in several
studies. In addition, a high incidence of CNS
involvement appears to be a feature of those
with marrow involvement. No studies have
suggested an advantage for maintenance
chemotherapy.
Anecdotal reports imply a reduced risk of
CNS involvement in regimes containing either
high-dose methotrexate or cytosine arabin-
oside. Key features which merit intensive
study are chemotherapy alone in Stage I and
II disease; the use of more effective com-
binations to improve complete remission
rates in Stage III disease; more effective
chemotherapy for Stage IV disease, and the
role of CNS prophylaxis. Finally, correlation
of newer classifications, either cytologically
or immunologically based, with response to
therapy and disease characteristics, is re-
quired. Although a preliminary report from
the NCI indicates that large-cleaved-cell
lymphomas have a good prognosis, this is in
contrast to another study which reports large
non-cleaved cells as a majority group within
the complete responders. Further detailed
clinical trials are thus essential.
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THE USE OF ANTIMETABOLITES IN LYMPHOMA CHEMOTHERAPY
J. F. SMYTH
From the Department of Clinical Oncology, University of Edinburgh
PROGRESS in the chemotherapy of lymph-
omas is restricted by the toxicity ofpresently
available drugs and the intrinsic or acquired
resistance that some lymphomas may display
towards them. An understanding of the
mechanisms of action of these compounds
illustrates that this toxicity is a reflection of
poor selectivity between the effects on tumour
cells and host tissues. Antimetabolites have
only recently been evaluated for lymphoma
treatment, but these compounds are particu-
larly accessible to biochemical study and
therefore to scientific therapeutic manipula-
tion. Early studies with the COMLA regime,
that incorporates the simultaneous adminis-
tration of methotrexate (MTX) and cytosine
arabinoside (Ara-C) followed by folinic acid,
have produced a significant rate of complete
and durable remissions in diffuse histiocytic
lymphoma. HowNever, experimental studies
indicate that writh simultaneous administra-
tion of MTX and Ara-C, these drugs can be
antagonistic, whereas synergism is obtained
if Ara-C is used before MTX. Exposure to
MTX decreases utilization of dUMP, with a
consequent accumulation ofdCTP. The latter
competes with the active metabolite ofAra-C,
AraCTP, thereby decreasing inhibition of
DNA polymerase. It would be of interest to
conduct clinical trials of the COMLA regime
in w%rhich Ara-C is administered prior to, not
concurrently with, MTX. Experimentally it
has been shown that the reversal of MTX
toxicitv with foliniic acid can be improved
upon wNith the use of combinations of purine
and pyrimidine nucleosides, since such
nucleoside "rescue" appears to have greater
selectivity for host tissues. Phase I clinical
trials have confirmed that nucleosides pro-
tect against MTX toxicity, and Phase II
studies nowi in progress should include
evaluation of this technique against lymph-
omas. The use of rescue techniques and the
development of less toxic analogues of exist-
ing drugs may improve the therapeutic index
of anti-lymphoma therapy, but the most
promising approach to selective chemo-
therapy is the rational design of news anti-
metabolites directed at defined enzyme loci.
The 2 enzymes adenosine deaminase (ADA)
and purine nucleoside phosphorylase (PNP)
are logical targets to select for inhibition,
since their congenital absence leads to
selective elimination oflymphocytes. Further-
more, ADA activity is greatly increased in
some lymphoid malignancies. Clinical trials
of the ADA inhibitor 2'-deoxycoformycin
have confirmed activity against lymphomas,
particularly of T-cell type. Research is con-
tinuing to identify a suitable inhibitor of
PNP. Such exploitation ofknowledge derived
from the study ofinborn errors ofmetabolism
affords a new approach to the selective
chemotherapy of lymphomas.
The organizers gratefully acknowledge the finan-
cial assistance from Lundbeck Ltd, Eli Lilly & Co.
Ltd, Farmitalia Carlo Erba Ltd, Lederle Labora-
tories, and Sigma Loindon.
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